Reimbursement Briefs: 340B, Exchange Plan Cost-Sharing, Part D Dual Eligibles
Executive Summary
HRSA’s Office of Pharmacy Affairs adds a new branch to oversee compliance in the 340B drug discount program; a PhRMA-funded study finds high coinsurance for drugs used by enrollees in many state exchange plans; OIG says Part D plans are covering a high percentage of drugs used by Medicare/Medicaid dual eligibles.
You may also be interested in...
Part D Plans Offer Broad Drug Access For Dual Eligibles, With Some Exceptions - OIG Study
Vytorin, Lunesta and Avapro are among eight drugs that are covered by fewer than 75% of plans available to beneficiaries eligible for both Medicare and Medicaid.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.